Search Results

John Streicher Dr. GPCR Podcast << Back to podcast list Dr. John Streicher About this episode Our guest in this episode of the Dr.GPCR podcast is Dr. John Streicher from the department of pharmacology at the University of Arizona. John started grad school in 1999 and spent some time figuring out what he was interested in. Today, John and his team focus on understanding how signal transduction cascades downstream of the opioid

Ep 145 with Dr John Janetzko Dr. GPCR Podcast << Back to podcast list Dr. John Janetzko About Dr. John's scientific content. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with

Ep 96 with R. Scott Struthers Dr. GPCR Podcast << Back to podcast list Scott Struthers R. R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

in Axons Joseph Duman Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Kinase TNIK Simeon R. He trained at the University of California at Berkeley with John Forte and the University of Washington Kimberley Tolias Lab Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Kinase TNIK Simeon R. Institute, UK 2Proteomics Science Technology Platform, The Francis Crick Institute, UK" About Simeon R. have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon R.

Authors and Affiliations John Stagg , David Allard . About John Stagg "John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital

Jennifer is currently an assistant professor of physiology at the Johns Hopkins School of Medicine. Jennifer Pluznick on the web John Hopkins Pluznick Lab Pubmed Ted Talk Dr.

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

About Eric Johansen "I will be a 6th year Ph.D student in the chemical biology interface program at Johns Eric Johansen on the web Johns Hopkins University Dr.

Raul Gainetdinov Raul R. Before SPBU, Raul R. Before joining the Department of Cell Biology in 1996 as a postdoc and becoming faculty at Duke in 2000 In 2018-2020, Raul R.

He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid

progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College.

After that, I worked at Johns Hopkins in Baltimore as a research assistant investigating mechanisms and

Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Randy then joined the faculty at the Emory University School of Medicine in 1999. Keck Foundation, and the John J. Abel Award from ASPET . Join me to learn more about Randy’s work, hear his insights on the GPCR field, and also hear the story

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&

Yamina Berchiche on the web D r.

I have 10 years of experience in the development and management of R&D projects and teams in the field In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics

In 2017 I officially joined the PhD program in the Department of Molecular Physiology and Biophysics Since I joined the lab, I became proficient in many In-vivo techniques, I adapted my arrestin recruitment John McCorvy , Dr. Dylan Eiger , and Joshua Gross. We are very excited about this event.

Optimized CRO Collaboration: Streamline internal R&D and external CRO workflows to prevent delays and focused execution accelerates preclinical milestones and maximizes the efficiency and return on your R&

Articles Kiyan Afzali The Perils and Guardrails of Modifying Signalling Proteins in Bioassays Read More John

John Traynor and Dr. Jessica Anand. 4.

He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma About Alex Serafini Alex was born and raised in the Bay Area and received his BS/MS Neuroscience from Johns Upon matriculating to Mount Sinai's MD/PhD program, he joined Dr.